Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung

BACKGROUND: Alectinib is a highly selective tyrosine kinase inhibitor of anaplastic lymphoma kinase (ALK) and provided a significantly prolonged progression-free survival compared with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) harboring rearrangements of the ALK gene....

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Surg Case Rep
Autores principales: Imanishi, Naoko, Yoneda, Kazue, Taira, Akihiro, Ichiki, Yoshinobu, Sato, Naoko, Hisaoka, Masanori, Tanaka, Fumihiro
Formato: Artigo
Lenguaje:Inglês
Publicado: Springer Berlin Heidelberg 2018
Materias:
Case Report
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5845085/
https://ncbi.nlm.nih.gov/pubmed/29524063
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40792-018-0430-7
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares